NEW YORK (GenomeWeb) – Alere announced this week that it will initiate a voluntary withdrawal of its anti-coagulation monitoring INRatio and INRatio2 PT/INR Monitoring System. The company said it is working with the US Food and Drug Administration to determine the most appropriate timing to discontinue the product, and will provide guidance on transitioning patients to an alternate product.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Human Longevity alleges that Craig Venter stole trade secrets in a lawsuit filed against the J. Craig Venter Institute.

A new paper critiques the analysis and conclusions of the Atacama mummy genome sequencing study.

An Associated Press poll finds that most US adults say they'd want to know whether they carried a gene variant predisposing them to an incurable disease.

In PLOS this week: transcription levels linked to uracil mutations, transcriptomic analysis of medicinal leech, and more.